Mirum Pharmaceuticals Reports Increased Revenue and Ongoing Strategic Developments in 2025

Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on rare diseases, reported a net loss of $23.4 million for the year ended December 31, 2025, a significant improvement compared to the $87.9 million net loss in 2024. The company's revenue increased substantially to $521.3 million in 2025, up from $336.4 million in the previous year. This growth was primarily driven by increased sales of Livmarli, its key product for cholestatic pruritus in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), as well as contributions from Cholbam and Ctexli, acquired from Travere Therapeutics. As of December 31, 2025, Mirum held $391.4 million in unrestricted cash, cash equivalents, and investments.

A key strategic development for Mirum in 2025 was the continued advancement of its product pipeline. The company is progressing with volixibat, a novel IBAT inhibitor, for the treatment of primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), with topline data from the VISTAS Phase 2b clinical trial in PSC expected in the second quarter of 2026. Additionally, the company is conducting the Phase 3 EXPAND study to explore Livmarli's efficacy in other rare cholestatic settings, with topline results anticipated in the fourth quarter of 2026. In January 2026, Mirum completed the acquisition of Bluejay Therapeutics, adding brelovitug, a monoclonal antibody for chronic hepatitis D virus (HDV) infection, to its portfolio.

Operationally, Mirum has been focused on expanding its commercial infrastructure and clinical development programs. As of December 31, 2025, the company employed 372 individuals, including clinical, research, and commercial personnel. The company is actively enrolling patients in the BLOOM Phase 2 clinical study of MRM-3379 for Fragile X Syndrome (FXS), with topline data expected in 2027. The company's commercial strategy involves direct sales in North America and certain European countries, as well as partnerships and distribution agreements in other regions.

Looking ahead, Mirum Pharmaceuticals aims to strengthen its position in rare and orphan diseases by commercializing its approved medicines, advancing its clinical pipeline, and acquiring additional rare disease products or companies. The company expects to continue investing in its commercial organization and research and development activities. While Mirum anticipates continued revenue growth, it also expects to incur net losses for the foreseeable future as it invests in its pipeline and commercial infrastructure. The company's future financial performance will depend on the successful commercialization of its current products and the development and approval of its product candidates.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases, particularly cholestatic liver and bile acid disorders. Its core products include LIVMARLI, CHOLBAM, and CHENODAL, targeting conditions like Alagille syndrome, PFIC, and CTX. The company leverages proprietary drug candidates, licensing agreements, and strategic acquisitions to address high unmet medical needs in niche markets worldwide.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.